Hoshang Jehangir Unwalla

Research topics

Matched from this investigator's NIH project titles and abstracts.

• Sleep and Circadian Rhythms
• Emotion and Affective Neuroscience

Active NIH awards

• Aberrant Micro-managing of the Airway Epithelial Transcriptome in HIV-associated COPD

  5R01HL167655-03

  NHLBI · FY 2025 · $639K

  PROJECT SUMMARY The long-term goal of this proposal is to identify the pathophysiology underlying HIV associated COPD. People living with HIV (PLWH) show increased incidence of COPD even when compensated for smoking status. MicroRNAs manage the cellular transcriptome and play important roles in health and disease. We have shown that HIV Tat and Transforming Growth Factor-beta (TGF-β) signaling dysregulate the airway microRNAome. Dysregulation of the microRNAome can effect multiple signaling pathways and this can affect cellular homeostasis. COPD is a multifactorial pathology and involves dysregulation of diverse signaling pathways that converge towards airway mitochondrial disfunction, circadian dysregulation, remodeling, inflammation, etc. TGF- β signaling is induced by both HIV Tat and cigarette smoke and this is significant since a significant proportion of PLWH are addicted to nicotine and smoke tobacco/cigarettes, possibly exacerbating their progression to COPD. Hence, Tat and TGF-β-induced aberrant microRNAome and its effects on the airway transcriptome can serve as an initiating events with downstream consequences on critical signaling nodes and pathways. Identifying these pathways and these critical signaling nodes can help tailor interventions to improve long-term pulmonary outcomes in PLWH. Lungs are important HIV reservoirs and we, and others have shown that airway epithelial cells express canonical HIV receptors and can be infected with HIV. A recent study shows that the bulk of HIV reservoirs are transcriptionally active even with suppressive cART. Hence, silencing HIV transcription can decrease HIV proteins like Tat in the airway. Gene editing using CRISPR/Cas9 has tremendous potential in eliminating HIV reservoirs and reports have shown excision of HIV from infected cells. However, CRISPR based HIV excision is vulnerable to viral escape as well as off-target effects. Cyclin T1, a component of P-TEFb, (heterodimer of cyclinT1 and CDK9) is bound by HIV Tat and plays a pivotal role HIV transcription and its inhibition abolishes HIV transcription. Hence CRISPR mediated CyclinT1 inactivation will completely block HIV transcription, locking the HIV proviral DNA in an inactive form. We will use our patented Pol II HIV LTR-drosophila hsp70 fusion monopromoter to co-express CyclinT1 gRNA and Cas9 (and effect CyclinT1 inactivation) only in HIV infected cells. Expression is self-limiting as our fusion promoter also requires CyclinT1 thereby minimizing off- target effects. Aim 1 will determine the mechanism by which HIV Tat and TGF-β dysregulate the airway microRNAome and its effects on the transcriptome to identify signaling pathways involved in HIV associated COPD. Aim 2 will use an inducible CRISPR syste to inactivate CyclinT1 only in HIV infected cells and lock the proviral DNA in a transcriptionally inactive state. Understanding the signaling pathways that promote HIV- associated COPD and silencing HIV transcription in reservoirs will prevent lung function decline and development of COPD in PLWH.

• Aberrant Micro-managing of the Airway Epithelial Transcriptome in HIV-associated COPD

  5R01HL167655-02

  NHLBI · FY 2024 · $633K

  PROJECT SUMMARY The long-term goal of this proposal is to identify the pathophysiology underlying HIV associated COPD. People living with HIV (PLWH) show increased incidence of COPD even when compensated for smoking status. MicroRNAs manage the cellular transcriptome and play important roles in health and disease. We have shown that HIV Tat and Transforming Growth Factor-beta (TGF-β) signaling dysregulate the airway microRNAome. Dysregulation of the microRNAome can effect multiple signaling pathways and this can affect cellular homeostasis. COPD is a multifactorial pathology and involves dysregulation of diverse signaling pathways that converge towards airway mitochondrial disfunction, circadian dysregulation, remodeling, inflammation, etc. TGF- β signaling is induced by both HIV Tat and cigarette smoke and this is significant since a significant proportion of PLWH are addicted to nicotine and smoke tobacco/cigarettes, possibly exacerbating their progression to COPD. Hence, Tat and TGF-β-induced aberrant microRNAome and its effects on the airway transcriptome can serve as an initiating events with downstream consequences on critical signaling nodes and pathways. Identifying these pathways and these critical signaling nodes can help tailor interventions to improve long-term pulmonary outcomes in PLWH. Lungs are important HIV reservoirs and we, and others have shown that airway epithelial cells express canonical HIV receptors and can be infected with HIV. A recent study shows that the bulk of HIV reservoirs are transcriptionally active even with suppressive cART. Hence, silencing HIV transcription can decrease HIV proteins like Tat in the airway. Gene editing using CRISPR/Cas9 has tremendous potential in eliminating HIV reservoirs and reports have shown excision of HIV from infected cells. However, CRISPR based HIV excision is vulnerable to viral escape as well as off-target effects. Cyclin T1, a component of P-TEFb, (heterodimer of cyclinT1 and CDK9) is bound by HIV Tat and plays a pivotal role HIV transcription and its inhibition abolishes HIV transcription. Hence CRISPR mediated CyclinT1 inactivation will completely block HIV transcription, locking the HIV proviral DNA in an inactive form. We will use our patented Pol II HIV LTR-drosophila hsp70 fusion monopromoter to co-express CyclinT1 gRNA and Cas9 (and effect CyclinT1 inactivation) only in HIV infected cells. Expression is self-limiting as our fusion promoter also requires CyclinT1 thereby minimizing off- target effects. Aim 1 will determine the mechanism by which HIV Tat and TGF-β dysregulate the airway microRNAome and its effects on the transcriptome to identify signaling pathways involved in HIV associated COPD. Aim 2 will use an inducible CRISPR syste to inactivate CyclinT1 only in HIV infected cells and lock the proviral DNA in a transcriptionally inactive state. Understanding the signaling pathways that promote HIV- associated COPD and silencing HIV transcription in reservoirs will prevent lung function decline and development of COPD in PLWH.

• Aberrant Micro-managing of the Airway Epithelial Transcriptome in HIV-associated COPD

  1R01HL167655-01A1

  NHLBI · FY 2023 · $654K

  PROJECT SUMMARY The long-term goal of this proposal is to identify the pathophysiology underlying HIV associated COPD. People living with HIV (PLWH) show increased incidence of COPD even when compensated for smoking status. MicroRNAs manage the cellular transcriptome and play important roles in health and disease. We have shown that HIV Tat and Transforming Growth Factor-beta (TGF-β) signaling dysregulate the airway microRNAome. Dysregulation of the microRNAome can effect multiple signaling pathways and this can affect cellular homeostasis. COPD is a multifactorial pathology and involves dysregulation of diverse signaling pathways that converge towards airway mitochondrial disfunction, circadian dysregulation, remodeling, inflammation, etc. TGF- β signaling is induced by both HIV Tat and cigarette smoke and this is significant since a significant proportion of PLWH are addicted to nicotine and smoke tobacco/cigarettes, possibly exacerbating their progression to COPD. Hence, Tat and TGF-β-induced aberrant microRNAome and its effects on the airway transcriptome can serve as an initiating events with downstream consequences on critical signaling nodes and pathways. Identifying these pathways and these critical signaling nodes can help tailor interventions to improve long-term pulmonary outcomes in PLWH. Lungs are important HIV reservoirs and we, and others have shown that airway epithelial cells express canonical HIV receptors and can be infected with HIV. A recent study shows that the bulk of HIV reservoirs are transcriptionally active even with suppressive cART. Hence, silencing HIV transcription can decrease HIV proteins like Tat in the airway. Gene editing using CRISPR/Cas9 has tremendous potential in eliminating HIV reservoirs and reports have shown excision of HIV from infected cells. However, CRISPR based HIV excision is vulnerable to viral escape as well as off-target effects. Cyclin T1, a component of P-TEFb, (heterodimer of cyclinT1 and CDK9) is bound by HIV Tat and plays a pivotal role HIV transcription and its inhibition abolishes HIV transcription. Hence CRISPR mediated CyclinT1 inactivation will completely block HIV transcription, locking the HIV proviral DNA in an inactive form. We will use our patented Pol II HIV LTR-drosophila hsp70 fusion monopromoter to co-express CyclinT1 gRNA and Cas9 (and effect CyclinT1 inactivation) only in HIV infected cells. Expression is self-limiting as our fusion promoter also requires CyclinT1 thereby minimizing off- target effects. Aim 1 will determine the mechanism by which HIV Tat and TGF-β dysregulate the airway microRNAome and its effects on the transcriptome to identify signaling pathways involved in HIV associated COPD. Aim 2 will use an inducible CRISPR syste to inactivate CyclinT1 only in HIV infected cells and lock the proviral DNA in a transcriptionally inactive state. Understanding the signaling pathways that promote HIV- associated COPD and silencing HIV transcription in reservoirs will prevent lung function decline and development of COPD in PLWH.